Nautilus, Inc. v. Biosig Instruments, Inc. , 134 S. Ct. 2120 ( 2014 )


Menu:
  • (Slip Opinion)              OCTOBER TERM, 2013                                       1
    Syllabus
    NOTE: Where it is feasible, a syllabus (headnote) will be released, as is
    being done in connection with this case, at the time the opinion is issued.
    The syllabus constitutes no part of the opinion of the Court but has been
    prepared by the Reporter of Decisions for the convenience of the reader.
    See United States v. Detroit Timber & Lumber Co., 
    200 U.S. 321
    , 337.
    SUPREME COURT OF THE UNITED STATES
    Syllabus
    NAUTILUS, INC. v. BIOSIG INSTRUMENTS, INC.
    CERTIORARI TO THE UNITED STATES COURT OF APPEALS FOR
    THE FEDERAL CIRCUIT
    No. 13–369.      Argued April 28, 2014—Decided June 2, 2014
    The Patent Act requires that a patent specification “conclude with one
    or more claims particularly pointing out and distinctly claiming the
    subject matter which the applicant regards as [the] invention.” 
    35 U.S. C
    . §112, ¶2. This case concerns the proper reading of the stat­
    ute’s clarity and precision demand.
    Assigned to respondent Biosig Instruments, Inc., the patent in dis­
    pute (the ’753 patent) involves a heart-rate monitor used with exer­
    cise equipment. Prior heart-rate monitors, the patent asserts, were
    often inaccurate in measuring the electrical signals accompanying
    each heartbeat (electrocardiograph or ECG signals) because of the
    presence of other electrical signals (electromyogram or EMG signals),
    generated by the user’s skeletal muscles, that can impede ECG signal
    detection. The invention claims to improve on prior art by detecting
    and processing ECG signals in a way that filters out the EMG inter­
    ference.
    Claim 1 of the ’753 patent, which contains the limitations critical to
    this dispute, refers to a “heart rate monitor for use by a user in asso­
    ciation with exercise apparatus and/or exercise procedures.” The
    claim “comprise[s],” among other elements, a cylindrical bar fitted
    with a display device; “electronic circuitry including a difference am­
    plifier”; and, on each half of the cylindrical bar, a “live” electrode and
    a “common” electrode “mounted . . . in spaced relationship with each
    other.”
    Biosig filed this patent infringement suit, alleging that Nautilus,
    Inc., without obtaining a license, sold exercise machines containing
    Biosig’s patented technology. The District Court, after conducting a
    hearing to determine the proper construction of the patent’s claims,
    granted Nautilus’ motion for summary judgment on the ground that
    2          NAUTILUS, INC. v. BIOSIG INSTRUMENTS, INC.
    Syllabus
    the claim term “in spaced relationship with each other” failed §112,
    ¶2’s definiteness requirement. The Federal Circuit reversed and re­
    manded, concluding that a patent claim passes the §112, ¶2 thresh­
    old so long as the claim is “amenable to construction,” and the claim,
    as construed, is not “insolubly ambiguous.” Under that standard, the
    court determined, the ’753 patent survived indefiniteness review.
    Held:
    1. A patent is invalid for indefiniteness if its claims, read in light of
    the patent’s specification and prosecution history, fail to inform, with
    reasonable certainty, those skilled in the art about the scope of the
    invention. The parties agree that definiteness is to be evaluated from
    the perspective of a person skilled in the relevant art, that claims are
    to be read in light of the patent’s specification and prosecution histo­
    ry, and that definiteness is to be measured as of the time of the pa­
    tent application. The parties disagree as to how much imprecision
    §112, ¶2 tolerates.
    Section 112’s definiteness requirement must take into account the
    inherent limitations of language. See Festo Corp. v. Shoketsu Kinzo-
    ku Kogyo Kabushiki Co., 
    535 U.S. 722
    , 731. On the one hand, some
    modicum of uncertainty is the “price of ensuring the appropriate in­
    centives for innovation,” 
    id., at 732;
    and patents are “not addressed to
    lawyers, or even to the public generally,” but to those skilled in the
    relevant art, Carnegie Steel Co. v. Cambria Iron Co., 
    185 U.S. 403
    ,
    437. At the same time, a patent must be precise enough to afford
    clear notice of what is claimed, thereby “ ‘appris[ing] the public of
    what is still open to them,’ ” Markman v. Westview Instruments, Inc.,
    
    517 U.S. 370
    , 373, in a manner that avoids “[a] zone of uncertainty
    which enterprise and experimentation may enter only at the risk of
    infringement claims,” United Carbon Co. v. Binney & Smith Co., 
    317 U.S. 228
    , 236. The standard adopted here mandates clarity, while
    recognizing that absolute precision is unattainable. It also accords
    with opinions of this Court stating that “the certainty which the law
    requires in patents is not greater than is reasonable, having regard
    to their subject-matter.” Minerals Separation, Ltd. v. Hyde, 
    242 U.S. 261
    , 270. Pp. 8–11.
    2. The Federal Circuit’s standard, which tolerates some ambiguous
    claims but not others, does not satisfy the statute’s definiteness re­
    quirement. The Court of Appeals inquired whether the ’753 patent’s
    claims were “amenable to construction” or “insolubly ambiguous,” but
    such formulations lack the precision §112, ¶2 demands. To tolerate
    imprecision just short of that rendering a claim “insolubly ambigu­
    ous” would diminish the definiteness requirement’s public-notice
    function and foster the innovation-discouraging “zone of uncertainty,”
    United 
    Carbon, 317 U.S., at 236
    , against which this Court has
    Cite as: 572 U. S. ____ (2014)                       3
    Syllabus
    warned. While some of the Federal Circuit’s fuller explications of the
    term “insolubly ambiguous” may come closer to tracking the statuto­
    ry prescription, this Court must ensure that the Federal Circuit’s test
    is at least “probative of the essential inquiry.” Warner-Jenkinson Co.
    v. Hilton Davis Chemical Co., 
    520 U.S. 17
    , 40. The expressions “in­
    solubly ambiguous” and “amenable to construction,” which permeate
    the Federal Circuit’s recent decisions concerning §112, ¶2, fall short
    in this regard and can leave courts and the patent bar at sea without
    a reliable compass. Pp. 11–13.
    3. This Court, as “a court of review, not of first view,” Cutter v. Wil-
    kinson, 
    544 U.S. 709
    , 718, n. 7, follows its ordinary practice of re­
    manding so that the Federal Circuit can reconsider, under the proper
    standard, whether the relevant claims in the ’753 patent are suffi­
    ciently definite, see, e.g., Johnson v. California, 
    543 U.S. 499
    , 515.
    Pp. 13–14.
    
    715 F.3d 891
    , vacated and remanded.
    GINSBURG, J., delivered the opinion for a unanimous Court.
    Cite as: 572 U. S. ____ (2014)                              1
    Opinion of the Court
    NOTICE: This opinion is subject to formal revision before publication in the
    preliminary print of the United States Reports. Readers are requested to
    notify the Reporter of Decisions, Supreme Court of the United States, Wash­
    ington, D. C. 20543, of any typographical or other formal errors, in order
    that corrections may be made before the preliminary print goes to press.
    SUPREME COURT OF THE UNITED STATES
    _________________
    No. 13–369
    _________________
    NAUTILUS, INC., PETITIONER v. BIOSIG
    INSTRUMENTS, INC.
    ON WRIT OF CERTIORARI TO THE UNITED STATES COURT OF
    APPEALS FOR THE FEDERAL CIRCUIT
    [June 2, 2014]
    JUSTICE GINSBURG delivered the opinion of the Court.
    The Patent Act requires that a patent specification
    “conclude with one or more claims particularly pointing
    out and distinctly claiming the subject matter which the
    applicant regards as [the] invention.” 
    35 U.S. C
    . §112, ¶2
    (2006 ed.) (emphasis added). This case, involving a heart­
    rate monitor used with exercise equipment, concerns the
    proper reading of the statute’s clarity and precision de­
    mand. According to the Federal Circuit, a patent claim
    passes the §112, ¶2 threshold so long as the claim is
    “amenable to construction,” and the claim, as construed, is
    not “insolubly ambiguous.” 
    715 F.3d 891
    , 898–899 (2013).
    We conclude that the Federal Circuit’s formulation, which
    tolerates some ambiguous claims but not others, does not
    satisfy the statute’s definiteness requirement. In place of
    the “insolubly ambiguous” standard, we hold that a patent
    is invalid for indefiniteness if its claims, read in light of
    the specification delineating the patent, and the prosecu­
    tion history, fail to inform, with reasonable certainty,
    those skilled in the art about the scope of the invention.
    Expressing no opinion on the validity of the patent-in-suit,
    2       NAUTILUS, INC. v. BIOSIG INSTRUMENTS, INC.
    Opinion of the Court
    we remand, instructing the Federal Circuit to decide the
    case employing the standard we have prescribed.
    I
    Authorized by the Constitution “[t]o promote the Pro­
    gress of Science and useful Arts, by securing for limited
    Times to . . . Inventors the exclusive Right to their . . .
    Discoveries,” Art. I, §8, cl. 8, Congress has enacted patent
    laws rewarding inventors with a limited monopoly.
    “Th[at] monopoly is a property right,” and “like any prop­
    erty right, its boundaries should be clear.” Festo Corp. v.
    Shoketsu Kinzoku Kogyo Kabushiki Co., 
    535 U.S. 722
    , 730
    (2002). See also Markman v. Westview Instruments, Inc.,
    
    517 U.S. 370
    , 373 (1996) (“It has long been understood
    that a patent must describe the exact scope of an inven­
    tion and its manufacture . . . .”). Thus, when Congress
    enacted the first Patent Act in 1790, it directed that pa­
    tent grantees file a written specification “containing a
    description . . . of the thing or things . . . invented or dis­
    covered,” which “shall be so particular” as to “distinguish
    the invention or discovery from other things before known
    and used.” Act of Apr. 10, 1790, §2, 1 Stat. 110.
    The patent laws have retained this requirement of
    definiteness even as the focus of patent construction has
    shifted. Under early patent practice in the United States,
    we have recounted, it was the written specification that
    “represented the key to the patent.” 
    Markman, 517 U.S., at 379
    . Eventually, however, patent applicants began to
    set out the invention’s scope in a separate section known
    as the “claim.” See generally 1 R. Moy, Walker on Patents
    §4.2, pp. 4–17 to 4–20 (4th ed. 2012). The Patent Act of
    1870 expressly conditioned the receipt of a patent on the
    inventor’s inclusion of one or more such claims, described
    with particularity and distinctness. See Act of July 8,
    1870, §26, 16 Stat. 201 (to obtain a patent, the inventor
    must “particularly point out and distinctly claim the part,
    Cite as: 572 U. S. ____ (2014)                      3
    Opinion of the Court
    improvement, or combination which [the inventor] claims
    as his invention or discovery”).
    The 1870 Act’s definiteness requirement survives today,
    largely unaltered. Section 112 of the Patent Act of 1952,
    applicable to this case, requires the patent applicant to
    conclude the specification with “one or more claims partic­
    ularly pointing out and distinctly claiming the subject
    matter which the applicant regards as his invention.” 
    35 U.S. C
    . §112, ¶2 (2006 ed.). A lack of definiteness renders
    invalid “the patent or any claim in suit.” §282, ¶2(3).1
    II
    A
    The patent in dispute, U. S. Patent No. 5,337,753 (’753
    patent), issued to Dr. Gregory Lekhtman in 1994 and
    assigned to respondent Biosig Instruments, Inc., concerns
    a heart-rate monitor for use during exercise. Previous
    heart-rate monitors, the patent asserts, were often inaccu­
    rate in measuring the electrical signals accompanying
    each heartbeat (electrocardiograph or ECG signals). The
    inaccuracy was caused by electrical signals of a different
    sort, known as electromyogram or EMG signals, generated
    by an exerciser’s skeletal muscles when, for example, she
    moves her arm, or grips an exercise monitor with her
    hand. These EMG signals can “mask” ECG signals and
    thereby impede their detection. App. 52, 147.
    ——————
    1 In the Leahy-Smith America Invents Act, Pub. L. 112–29, 125 Stat.
    284, enacted in 2011, Congress amended several parts of the Patent
    Act. Those amendments modified §§112 and 282 in minor respects not
    pertinent here. In any event, the amended versions of those provisions
    are inapplicable to patent applications filed before September 16, 2012,
    and proceedings commenced before September 16, 2011. See §§4(e),
    15(c), 20(l), 125 Stat. 297, 328, 335, notes following 
    35 U.S. C
    . §§2, 111,
    119. Here, the application for the patent-in-suit was filed in 1992, and
    the relevant court proceedings were initiated in 2010. Accordingly, this
    opinion’s citations to the Patent Act refer to the 2006 edition of the
    United States Code.
    4         NAUTILUS, INC. v. BIOSIG INSTRUMENTS, INC.
    Opinion of the Court
    Dr. Lekhtman’s invention claims to improve on prior art
    by eliminating that impediment. The invention focuses on
    a key difference between EMG and ECG waveforms: while
    ECG signals detected from a user’s left hand have a polar­
    ity opposite to that of the signals detected from her right
    hand,2 EMG signals from each hand have the same polar-
    ity. The patented device works by measuring equalized
    EMG signals detected at each hand and then using cir­
    cuitry to subtract the identical EMG signals from each
    other, thus filtering out the EMG interference.
    As relevant here, the ’753 patent describes a heart-rate
    monitor contained in a hollow cylindrical bar that a user
    grips with both hands, such that each hand comes into
    contact with two electrodes, one “live” and one “common.”
    The device is illustrated in figure 1 of the patent, 
    id., at 41,
    reproduced in the Appendix to this opinion.
    Claim 1 of the ’753 patent, which contains the limita­
    tions critical to this dispute, refers to a “heart rate monitor
    for use by a user in association with exercise apparatus
    and/or exercise procedures.” 
    Id., at 61.
    The claim “com­
    prise[s],” among other elements, an “elongate member”
    (cylindrical bar) with a display device; “electronic circuitry
    including a difference amplifier”; and, on each half of the
    cylindrical bar, a live electrode and a common electrode
    “mounted . . . in spaced relationship with each other.”
    Ibid.3 The claim sets forth additional elements, including
    that the cylindrical bar is to be held in such a way that
    each of the user’s hands “contact[s]” both electrodes on
    each side of the bar. 
    Id., at 62.
    Further, the EMG signals
    detected by the two electrode pairs are to be “of substan­
    ——————
    2 This difference in polarity occurs because the heart is not aligned
    vertically in relation to the center of the body; the organ tilts leftward
    from apex to bottom. App. 213.
    3 As depicted in figure 1 of the patent, 
    id., at 41,
    reproduced in the
    Appendix to this opinion, the live electrodes are identified by numbers
    9 and 13, and the common electrodes, by 11 and 15.
    Cite as: 572 U. S. ____ (2014)           5
    Opinion of the Court
    tially equal magnitude and phase” so that the difference
    amplifier will “produce a substantially zero [EMG] signal”
    upon subtracting the signals from one another. 
    Ibid. B The dispute
    between the parties arose in the 1990’s,
    when Biosig allegedly disclosed the patented technology to
    StairMaster Sports Medical Products, Inc. According to
    Biosig, StairMaster, without ever obtaining a license, sold
    exercise machines that included Biosig’s patented technol­
    ogy, and petitioner Nautilus, Inc., continued to do so after
    acquiring the StairMaster brand. In 2004, based on these
    allegations, Biosig brought a patent infringement suit
    against Nautilus in the U. S. District Court for the South­
    ern District of New York.
    With Biosig’s lawsuit launched, Nautilus asked the U. S.
    Patent and Trademark Office (PTO) to reexamine the ’753
    patent.     The reexamination proceedings centered on
    whether the patent was anticipated or rendered obvious
    by prior art—principally, a patent issued in 1984 to an
    inventor named Fujisaki, which similarly disclosed a
    heart-rate monitor using two pairs of electrodes and a
    difference amplifier. Endeavoring to distinguish the ’753
    patent from prior art, Biosig submitted a declaration from
    Dr. Lekhtman. The declaration attested, among other
    things, that the ’753 patent sufficiently informed a person
    skilled in the art how to configure the detecting electrodes
    so as “to produce equal EMG [signals] from the left and
    right hands.” 
    Id., at 160.
    Although the electrodes’ design
    variables—including spacing, shape, size, and material—
    cannot be standardized across all exercise machines, Dr.
    Lekhtman explained, a skilled artisan could undertake a
    “trial and error” process of equalization. This would entail
    experimentation with different electrode configurations in
    order to optimize EMG signal cancellation. 
    Id., at 155–
    6        NAUTILUS, INC. v. BIOSIG INSTRUMENTS, INC.
    Opinion of the Court
    156, 158.4 In 2010, the PTO issued a determination con­
    firming the patentability of the ’753 patent’s claims.
    Biosig thereafter reinstituted its infringement suit,
    which the parties had voluntarily dismissed without prej­
    udice while PTO reexamination was underway. In 2011,
    the District Court conducted a hearing to determine the
    proper construction of the patent’s claims, see Markman v.
    Westview Instruments, Inc., 
    517 U.S. 370
    (1996) (claim
    construction is a matter of law reserved for court decision),
    including the claim term “in spaced relationship with each
    other.” According to Biosig, that “spaced relationship”
    referred to the distance between the live electrode and the
    common electrode in each electrode pair. Nautilus, seizing
    on Biosig’s submissions to the PTO during the reexamina­
    tion, maintained that the “spaced relationship” must be a
    distance “greater than the width of each electrode.” App.
    245. The District Court ultimately construed the term to
    mean “there is a defined relationship between the live
    electrode and the common electrode on one side of the
    cylindrical bar and the same or a different defined rela­
    tionship between the live electrode and the common elec­
    trode on the other side of the cylindrical bar,” without any
    reference to the electrodes’ width. App. to Pet. for Cert.
    43a–44a.
    Nautilus moved for summary judgment, arguing that
    the term “spaced relationship,” as construed, was indefi­
    nite under §112, ¶2. The District Court granted the mo­
    tion. Those words, the District Court concluded, “did not
    tell [the court] or anyone what precisely the space should
    ——————
    4 Dr. Lekhtman’s declaration also referred to an expert report pre­
    pared by Dr. Henrietta Galiana, Chair of the Department of Biomedical
    Engineering at McGill University, for use in the infringement litiga­
    tion. That report described how Dr. Galiana’s laboratory technician,
    equipped with a wooden dowel, wire, metal foil, glue, electrical tape,
    and the drawings from the ’753 patent, was able in two hours to build a
    monitor that “worked just as described in the . . . patent.” 
    Id., at 226.
                     Cite as: 572 U. S. ____ (2014)           7
    Opinion of the Court
    be,” or even supply “any parameters” for determining the
    appropriate spacing. 
    Id., at 72a.
       The Federal Circuit reversed and remanded. A claim is
    indefinite, the majority opinion stated, “only when it is
    ‘not amenable to construction’ or ‘insolubly ambiguous.’ ”
    
    715 F.3d 891
    , 898 (2013) (quoting Datamize, LLC v.
    Plumtree Software, Inc., 
    417 F.3d 1342
    , 1347 (CA Fed.
    2005)). Under that standard, the majority determined, the
    ’753 patent survived indefiniteness review. Considering
    first the “intrinsic evidence”—i.e., the claim language, the
    specification, and the prosecution history—the majority
    discerned “certain inherent parameters of the claimed
    apparatus, which to a skilled artisan may be sufficient to
    understand the metes and bounds of ‘spaced relation­
    ship.’ 
    715 F.3d, at 899
    . These sources of meaning, the
    majority explained, make plain that the distance separat­
    ing the live and common electrodes on each half of the bar
    “cannot be greater than the width of a user’s hands”; that
    is so “because claim 1 requires the live and common elec­
    trodes to independently detect electrical signals at two
    distinct points of a hand.” 
    Ibid. Furthermore, the major­
    ity noted, the intrinsic evidence teaches that this distance
    cannot be “infinitesimally small, effectively merging the
    live and common electrodes into a single electrode with
    one detection point.” 
    Ibid. The claim’s functional
    provi­
    sions, the majority went on to observe, shed additional
    light on the meaning of “spaced relationship.” Surveying
    the record before the PTO on reexamination, the majority
    concluded that a skilled artisan would know that she could
    attain the indicated functions of equalizing and removing
    EMG signals by adjusting design variables, including
    spacing.
    In a concurring opinion, Judge Schall reached the ma­
    jority’s result employing “a more limited analysis.” 
    Id., at 905.
    Judge Schall accepted the majority’s recitation of the
    definiteness standard, under which claims amenable to
    8       NAUTILUS, INC. v. BIOSIG INSTRUMENTS, INC.
    Opinion of the Court
    construction are nonetheless indefinite when “the con­
    struction remains insolubly ambiguous.” 
    Ibid. (internal quotation marks
    omitted). The District Court’s construc­
    tion of “spaced relationship,” Judge Schall maintained,
    was sufficiently clear: the term means “there is a fixed
    spatial relationship between the live electrode and the
    common electrode” on each side of the cylindrical bar.
    
    Ibid. Judge Schall agreed
    with the majority that the
    intrinsic evidence discloses inherent limits of that spacing.
    But, unlike the majority, Judge Schall did not “presum[e]
    a functional linkage between the ‘spaced relationship’
    limitation and the removal of EMG signals.” 
    Id., at 906.
    Other limitations of the claim, in his view, and not the
    “ ‘spaced relationship’ limitation itself,” “included a func­
    tional requirement to remove EMG signals.” 
    Ibid. We granted certiorari,
    571 U. S. ___ (2014), and now
    vacate and remand.
    III
    A
    Although the parties here disagree on the dispositive
    question—does the ’753 patent withstand definiteness
    scrutiny—they are in accord on several aspects of the
    §112, ¶2 inquiry. First, definiteness is to be evaluated
    from the perspective of someone skilled in the relevant art.
    See, e.g., General Elec. Co. v. Wabash Appliance Corp., 
    304 U.S. 364
    , 371 (1938). See also §112, ¶1 (patent’s specifi­
    cation “shall contain a written description of the invention,
    and of the manner and process of making and using it, in
    such full, clear, concise, and exact terms as to enable any
    person skilled in the art to which it pertains, or with which
    it is most nearly connected, to make and use the same”
    (emphasis added)). Second, in assessing definiteness,
    claims are to be read in light of the patent’s specification
    and prosecution history. See, e.g., United States v. Adams,
    
    383 U.S. 39
    , 48–49 (1966) (specification); Festo Corp. v.
    Cite as: 572 U. S. ____ (2014)                9
    Opinion of the Court
    Shoketsu Kinzoku Kogyo Kabushiki Co., 
    535 U.S. 722
    , 741
    (2002) (prosecution history). Third, “[d]efiniteness is
    measured from the viewpoint of a person skilled in [the]
    art at the time the patent was filed.” Brief for Respondent
    55 (emphasis added). See generally Sarnoff & Manzo, An
    Introduction to, Premises of, and Problems With Patent
    Claim Construction, in Patent Claim Construction in the
    Federal Circuit 9 (E. Manzo ed. 2014) (“Patent claims . . .
    should be construed from an objective perspective of a
    [skilled artisan], based on what the applicant actually
    claimed, disclosed, and stated during the application
    process.”).
    The parties differ, however, in their articulations of just
    how much imprecision §112, ¶2 tolerates. In Nautilus’
    view, a patent is invalid when a claim is “ambiguous, such
    that readers could reasonably interpret the claim’s scope
    differently.” Brief for Petitioner 37. Biosig and the Solici­
    tor General would require only that the patent provide
    reasonable notice of the scope of the claimed invention.
    See Brief for Respondent 18; Brief for United States as
    Amicus Curiae 9–10.
    Section 112, we have said, entails a “delicate balance.”
    
    Festo, 535 U.S., at 731
    . On the one hand, the definiteness
    requirement must take into account the inherent limita­
    tions of language. See 
    ibid. Some modicum of
    uncertainty,
    the Court has recognized, is the “price of ensuring the
    appropriate incentives for innovation.” 
    Id., at 732.
    One
    must bear in mind, moreover, that patents are “not ad­
    dressed to lawyers, or even to the public generally,” but
    rather to those skilled in the relevant art. Carnegie Steel
    Co. v. Cambria Iron Co., 
    185 U.S. 403
    , 437 (1902) (also
    stating that “any description which is sufficient to apprise
    [steel manufacturers] in the language of the art of the
    definite feature of the invention, and to serve as a warning
    to others of what the patent claims as a monopoly, is
    sufficiently definite to sustain the patent”).5
    ——————
    5 See   also Eibel Process Co. v. Minnesota & Ontario Paper Co., 261
    10        NAUTILUS, INC. v. BIOSIG INSTRUMENTS, INC.
    Opinion of the Court
    At the same time, a patent must be precise enough to
    afford clear notice of what is claimed, thereby “ ‘appris[ing]
    the public of what is still open to them.’ ” 
    Markman, 517 U.S., at 373
    (quoting McClain v. Ortmayer, 
    141 U.S. 419
    ,
    424 (1891)).6 Otherwise there would be “[a] zone of uncer­
    tainty which enterprise and experimentation may enter
    only at the risk of infringement claims.” United Carbon
    Co. v. Binney & Smith Co., 
    317 U.S. 228
    , 236 (1942). And
    absent a meaningful definiteness check, we are told, pa­
    tent applicants face powerful incentives to inject ambigu-
    ity into their claims. See Brief for Petitioner 30–32 (citing
    patent treatises and drafting guides). See also Federal
    Trade Commission, The Evolving IP Marketplace: Align­
    ing Patent Notice and Remedies With Competition 85
    (2011) (quoting testimony that patent system fosters “an
    incentive to be as vague and ambiguous as you can with
    your claims” and “defer clarity at all costs”).7 Eliminating
    that temptation is in order, and “the patent drafter is in
    the best position to resolve the ambiguity in . . . patent
    ——————
    U. S. 45, 58, 65–66 (1923) (upholding as definite a patent for an im­
    provement to a paper-making machine, which provided that a wire be
    placed at a “high” or “substantial elevation,” where “readers . . . skilled
    in the art of paper making and versed in the use of the . . . machine”
    would have “no difficulty . . . in determining . . . the substantial [eleva­
    tion] needed” for the machine to operate as specified).
    6 See also United Carbon Co. v. Binney & Smith Co., 
    317 U.S. 228
    ,
    236 (1942) (“The statutory requirement of particularity and distinct­
    ness in claims is met only when they clearly distinguish what is
    claimed from what went before in the art and clearly circumscribe what
    is foreclosed from future enterprise.”); General Elec. Co. v. Wabash
    Appliance Corp., 
    304 U.S. 364
    , 369 (1938) (“The limits of a patent must
    be known for the protection of the patentee, the encouragement of the
    inventive genius of others and the assurance that the subject of the
    patent will be dedicated ultimately to the public.”).
    7 Online at http: / / www. ftc.gov / sites / default / files / documents /
    reports/evolving-ip-marketplace-aligning-patent-notice-and-remedies-
    competition - report -federal- trade / 110307patentreport.pdf (as visited
    May 30, 2014, and available in Clerk of Court’s case file).
    Cite as: 572 U. S. ____ (2014)                       11
    Opinion of the Court
    claims.” Halliburton Energy Servs., Inc. v. M–I LLC, 
    514 F.3d 1244
    , 1255 (CA Fed. 2008). See also Hormone Re-
    search Foundation, Inc. v. Genentech, Inc., 
    904 F.2d 1558
    ,
    1563 (CA Fed. 1990) (“It is a well-established axiom in
    patent law that a patentee is free to be his or her own
    lexicographer . . . .”).
    To determine the proper office of the definiteness com­
    mand, therefore, we must reconcile concerns that tug in
    opposite directions. Cognizant of the competing concerns,
    we read §112, ¶2 to require that a patent’s claims, viewed
    in light of the specification and prosecution history, inform
    those skilled in the art about the scope of the invention
    with reasonable certainty. The definiteness requirement,
    so understood, mandates clarity, while recognizing that
    absolute precision is unattainable. The standard we adopt
    accords with opinions of this Court stating that “the cer­
    tainty which the law requires in patents is not greater
    than is reasonable, having regard to their subject-matter.”
    Minerals Separation, Ltd. v. Hyde, 
    242 U.S. 261
    , 270
    (1916). See also United 
    Carbon, 317 U.S., at 236
    (“claims
    must be reasonably clear-cut”); 
    Markman, 517 U.S., at 389
    (claim construction calls for “the necessarily sophisti­
    cated analysis of the whole document,” and may turn on
    evaluations of expert testimony).
    B
    In resolving Nautilus’ definiteness challenge, the Fed-
    eral Circuit asked whether the ’753 patent’s claims were
    “amenable to construction” or “insolubly ambiguous.”
    Those formulations can breed lower court confusion,8 for
    ——————
    8 See, e.g., Every Penny Counts, Inc. v. Wells Fargo Bank, N. A., ___
    F. Supp. 2d ___, ___, 
    2014 WL 869092
    , *4 (MD Fla., Mar. 5, 2014)
    (finding that “the account,” as used in claim, “lacks definiteness,”
    because it might mean several different things and “no informed and
    confident choice is available among the contending definitions,” but
    that “the extent of the indefiniteness . . . falls far short of the ‘insoluble
    12       NAUTILUS, INC. v. BIOSIG INSTRUMENTS, INC.
    Opinion of the Court
    they lack the precision §112, ¶2 demands. It cannot be
    sufficient that a court can ascribe some meaning to a
    patent’s claims; the definiteness inquiry trains on the
    understanding of a skilled artisan at the time of the pa­
    tent application, not that of a court viewing matters
    post hoc. To tolerate imprecision just short of that render­
    ing a claim “insolubly ambiguous” would diminish the
    definiteness requirement’s public-notice function and
    foster the innovation-discouraging “zone of uncertainty,”
    United 
    Carbon, 317 U.S., at 236
    , against which this Court
    has warned.
    Appreciating that “terms like ‘insolubly ambiguous’ may
    not be felicitous,” Brief for Respondent 34, Biosig argues
    the phrase is a shorthand label for a more probing inquiry
    that the Federal Circuit applies in practice. The Federal
    Circuit’s fuller explications of the term “insolubly ambigu­
    ous,” we recognize, may come closer to tracking the statu­
    tory prescription. See, 
    e.g., 715 F.3d, at 898
    (case below)
    (“[I]f reasonable efforts at claim construction result in a
    definition that does not provide sufficient particularity
    and clarity to inform skilled artisans of the bounds of the
    claim, the claim is insolubly ambiguous and invalid for
    indefiniteness.” (internal quotation marks omitted)). But
    although this Court does not “micromanag[e] the Federal
    Circuit’s particular word choice” in applying patent-law
    doctrines, we must ensure that the Federal Circuit’s test is
    at least “probative of the essential inquiry.” Warner-
    Jenkinson Co. v. Hilton Davis Chemical Co., 
    520 U.S. 17
    ,
    40 (1997). Falling short in that regard, the expressions
    “insolubly ambiguous” and “amenable to construction”
    permeate the Federal Circuit’s recent decisions concerning
    §112, ¶2’s requirement.9 We agree with Nautilus and its
    ——————
    ambiguity’ required to invalidate the claim”).
    9 E.g., Hearing Components, Inc. v. Shure Inc., 
    600 F.3d 1357
    , 1366
    (CA Fed. 2010) (“the definiteness of claim terms depends on whether
    Cite as: 572 U. S. ____ (2014)                     13
    Opinion of the Court
    amici that such terminology can leave courts and the
    patent bar at sea without a reliable compass.10
    IV
    Both here and in the courts below, the parties have
    advanced conflicting arguments as to the definiteness of
    the claims in the ’753 patent. Nautilus maintains that the
    claim term “spaced relationship” is open to multiple inter­
    pretations reflecting markedly different understandings of
    ——————
    those terms can be given any reasonable meaning”); Datamize, LLC v.
    Plumtree Software, Inc., 
    417 F.3d 1342
    , 1347 (CA Fed. 2005) (“Only
    claims ‘not amenable to construction’ or ‘insolubly ambiguous’ are
    indefinite.”); Exxon Research & Engineering Co. v. United States, 
    265 F.3d 1371
    , 1375 (CA Fed. 2001) (“If a claim is insolubly ambiguous,
    and no narrowing construction can properly be adopted, we have held
    the claim indefinite.”). See also Dept. of Commerce, Manual of Patent
    Examining Procedure §2173.02(I), p. 294 (9th ed. 2014) (PTO manual
    describing Federal Circuit’s test as upholding a claim’s validity “if some
    meaning can be gleaned from the language”).
    10 The Federal Circuit suggests that a permissive definiteness stand­
    ard “ ‘accord[s] respect to the statutory presumption of patent validity.’ ”
    
    715 F.3d 891
    , 902 (2013) (quoting Exxon 
    Research, 265 F.3d, at 1375
    ).
    See also §282, ¶1 (“[a] patent shall be presumed valid,” and “[t]he
    burden of establishing invalidity of a patent or any claim thereof shall
    rest on the party asserting such invalidity”); Microsoft Corp. v. i4i Ltd.
    Partnership, 564 U. S. ___, ___ (2011) (slip op., at 1) (invalidity defenses
    must be proved by “clear and convincing evidence”). As the parties
    appear to agree, however, this presumption of validity does not alter
    the degree of clarity that §112, ¶2 demands from patent applicants; to
    the contrary, it incorporates that definiteness requirement by refer­
    ence. See §282, ¶2(3) (defenses to infringement actions include
    “[i]nvalidity of the patent or any claim in suit for failure to comply with
    . . . any requirement of [§112]”).
    The parties nonetheless dispute whether factual findings subsidiary
    to the ultimate issue of definiteness trigger the clear-and-convincing­
    evidence standard and, relatedly, whether deference is due to the PTO’s
    resolution of disputed issues of fact. We leave these questions for
    another day. The court below treated definiteness as “a legal issue
    [the] court reviews without 
    deference,” 715 F.3d, at 897
    , and Biosig has
    not called our attention to any contested factual matter—or PTO
    determination thereof—pertinent to its infringement claims.
    14       NAUTILUS, INC. v. BIOSIG INSTRUMENTS, INC.
    Opinion of the Court
    the patent’s scope, as exemplified by the disagreement
    among the members of the Federal Circuit panel.11 Biosig
    responds that “spaced relationship,” read in light of the
    specification and as illustrated in the accompanying draw­
    ings, delineates the permissible spacing with sufficient
    precision.
    “[M]indful that we are a court of review, not of first
    view,” Cutter v. Wilkinson, 
    544 U.S. 709
    , 718, n. 7 (2005),
    we decline to apply the standard we have announced to
    the controversy between Nautilus and Biosig. As we have
    explained, the Federal Circuit invoked a standard more
    amorphous than the statutory definiteness requirement
    allows. We therefore follow our ordinary practice of re­
    manding so that the Court of Appeals can reconsider,
    under the proper standard, whether the relevant claims in
    the ’753 patent are sufficiently definite. See, e.g., Johnson
    v. California, 
    543 U.S. 499
    , 515 (2005); Gasperini v. Cen-
    ter for Humanities, Inc., 
    518 U.S. 415
    , 438 (1996).
    *   *      *
    For the reasons stated, we vacate the judgment of the
    United States Court of Appeals for the Federal Circuit and
    remand the case for further proceedings consistent with
    this opinion.
    It is so ordered.
    ——————
    11 Notably, however, all three panel members found Nautilus’ argu­
    ments unavailing.
    Cite as: 572 U. S. ____ (2014)   15
    Opinion of the Court
    Appendix to opinion of the Court
    APPENDIX
    Patent No. 5,337,753, Figure 1
    

Document Info

Docket Number: 13–369.

Citation Numbers: 189 L. Ed. 2d 37, 134 S. Ct. 2120, 2014 U.S. LEXIS 3818, 82 U.S.L.W. 4433, 572 U.S. 898, 24 Fla. L. Weekly Fed. S 799, 110 U.S.P.Q. 2d (BNA) 1688, 2014 WL 2440536

Judges: Ginsburg

Filed Date: 6/2/2014

Precedential Status: Precedential

Modified Date: 10/19/2024

Authorities (16)

Carnegie Steel Co. v. Cambria Iron Co. , 22 S. Ct. 698 ( 1902 )

Cutter v. Wilkinson , 125 S. Ct. 2113 ( 2005 )

Minerals Separation, Ltd. v. Hyde , 37 S. Ct. 82 ( 1916 )

McClain v. Ortmayer , 12 S. Ct. 76 ( 1891 )

United Carbon Co. v. Binney & Smith Co. , 63 S. Ct. 165 ( 1942 )

Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co. , 122 S. Ct. 1831 ( 2002 )

General Electric Co. v. Wabash Appliance Corp. , 58 S. Ct. 899 ( 1938 )

Hearing Components, Inc. v. Shure Inc. , 600 F.3d 1357 ( 2010 )

Halliburton Energy Services, Inc. v. M-I LLC , 514 F.3d 1244 ( 2008 )

hormone-research-foundation-inc-and-hoffmann-laroche-inc-v-genentech , 904 F.2d 1558 ( 1990 )

United States v. Detroit Timber & Lumber Co. , 26 S. Ct. 282 ( 1906 )

United States v. Adams , 86 S. Ct. 708 ( 1966 )

MARKMAN Et Al. v. WESTVIEW INSTRUMENTS, INC., Et Al. , 116 S. Ct. 1384 ( 1996 )

Gasperini v. Center for Humanities, Inc. , 116 S. Ct. 2211 ( 1996 )

Exxon Research and Engineering Company v. United States , 265 F.3d 1371 ( 2001 )

Johnson v. California , 125 S. Ct. 1141 ( 2005 )

View All Authorities »

Cited By (69)

Driessen v. Sony Music Entertainment , 640 F. App'x 892 ( 2016 )

Endo Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc. ( 2018 )

Liqwd, Inc. v. L'Oreal USA, Inc. ( 2018 )

Capital Security Systems, Inc. v. Ncr Corporation ( 2018 )

Ethicon Endo-Surgery, Inc. v. Covidien, Inc. , 796 F.3d 1312 ( 2015 )

Media Rights Technologies, Inc. v. Capital One Financial ... , 800 F.3d 1366 ( 2015 )

The Dow Chemical Company v. Nova Chemicals Corporation , 803 F.3d 620 ( 2015 )

The Dow Chemical Company v. Nova Chemicals Corporation , 809 F.3d 1223 ( 2015 )

Akzo Nobel Coatings, Inc. v. Dow Chemical Company , 811 F.3d 1334 ( 2016 )

Ultimatepointer, L.L.C. v. Nintendo Co Ltd , 816 F.3d 816 ( 2016 )

Azure Networks, LLC v. Csr, Plc , 771 F.3d 1336 ( 2014 )

Warsaw Orthopedic, Inc. v. Nuvasive, Inc. , 778 F.3d 1365 ( 2015 )

Eli Lilly and Company v. Teva Parenteral Medicines , 845 F.3d 1357 ( 2017 )

Tinnus Enterprises, LLC v. Telebrands Corporation , 846 F.3d 1190 ( 2017 )

The Medicines Company v. Mylan, Inc. , 853 F.3d 1296 ( 2017 )

Mastermine Software, Inc. v. Microsoft Corporation , 874 F.3d 1307 ( 2017 )

Basf Corporation v. Johnson Matthey Inc. , 875 F.3d 1360 ( 2017 )

Exmark Manufacturing Co. v. Briggs & Stratton Power ... , 879 F.3d 1332 ( 2018 )

Berkheimer v. Hp Inc. , 881 F.3d 1360 ( 2018 )

Knowles Electronics LLC v. Cirrus Logic, Inc. , 883 F.3d 1358 ( 2018 )

View All Citing Opinions »